124492-04-2 Usage
General Description
(S)-1,4-DITHIA-7-AZASPIRO[4.4]NONANE-8-CARBOXYLIC ACID is a chemical compound with a unique molecular structure, containing sulfur and nitrogen atoms in a spiro ring system. It is a carboxylic acid with potential applications in organic synthesis and pharmaceutical research. The compound's spiro ring structure makes it an interesting candidate for use in the design of novel drug molecules, as it can potentially interact with biological targets in a unique and specific manner. Further research and experimentation may reveal the full range of potential uses for this compound in various fields of science and technology.
Check Digit Verification of cas no
The CAS Registry Mumber 124492-04-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,4,4,9 and 2 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 124492-04:
(8*1)+(7*2)+(6*4)+(5*4)+(4*9)+(3*2)+(2*0)+(1*4)=112
112 % 10 = 2
So 124492-04-2 is a valid CAS Registry Number.
124492-04-2Relevant articles and documents
Angiotensin Converting Enzyme Inhibitors: Spirapril and Related Compounds
Smith, Elizabeth M.,Swiss, Gerald F.,Neustadt, Bernard R.,McNamara, Paul,Gold, Elijah H.,et al.
, p. 1600 - 1606 (2007/10/02)
The synthesis of spirapril (5), spiraprilat (25), their RSS stereoisomers, and their glycyl (18b) and lysyl (36, 37) analogues is described.These compounds were evaluated in vivo for inhibition of angiotensin converting enzyme (ACE), and selected compounds were evaluated for in vitro ACE inhibition (spirapril ID50 16 μg/kg; spiraprilat IC50 0.8 nM, ID50 8 μg/kg).In anesthetized rats, iv, esters 5 and 36 are more potent than enalapril, and diacids 25 and 37 are more potent than enalaprilat in vitro.In the conscious rats, orally, 5 and enalapril (2) showed potent and sustained activity at doses of 0.03-1 and 0.1-1 mg/kg, respectively.From this work, spirapril was selected for clinical evaluation as an antihypertensive agent.
